Related references
Note: Only part of the references are listed.Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Jonathan W. Goldman et al.
LANCET ONCOLOGY (2021)
Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumab
Wei-Xiang Qi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Neutrophil or platelet-to-lymphocyte ratios in blood are associated with poor prognosis of pulmonary large cell neuroendocrine carcinoma
Minxing Shi et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab
A. Simonaggio et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Platelet-to-lymphocyte ratio and CA19-9 are simple and informative prognostic factors in patients with resected pancreatic cancer
Ionut Negoi et al.
HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL (2019)
Emerging therapies for small cell lung cancer
Sen Yang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz-Ares et al.
LANCET (2019)
First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China
Ling-Yu Li et al.
CHINESE MEDICAL JOURNAL (2019)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
Stefan Diem et al.
LUNG CANCER (2017)
Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
Min Deng et al.
ONCOTARGET (2017)
Prognostic Significance of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Oncologic Outcomes of Esophageal Cancer: A Systematic Review and Meta-analysis
Hariruk Yodying et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer
Leora Horn et al.
ONCOLOGIST (2016)
Elevated Serum Neutrophil to Lymphocyte and Platelet to Lymphocyte Ratios Could be Useful in Lung Cancer Diagnosis
Yasemin Kemal et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2014)
Cigarette smoking and lung cancerurelative risk estimates for the major histological types from a pooled analysis of case-control studies
Beate Pesch et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: Results from a randomized phase III trial with 5 years' follow-up
S Sundstrom et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
